Hum Vaccin Immunother
. 2020 Sep 16;1-18.
doi: 10.1080/21645515.2020.1812313. Online ahead of print.
Leveraging on the genomics and immunopathology of SARS-CoV-2 for vaccines development: prospects and challenges
Idris Nasir Abdullahi 1 , Anthony Uchenna Emeribe 2 , Hafeez Aderinsayo Adekola 3 , Sharafudeen Dahiru Abubakar 1 , Amos Dangana 4 , Halima Ali Shuwa 5 , Sunday Theophilus Nwoba 6 , Jelili Olaide Mustapha 7 , Muyideen Titilope Haruna 8 , Kafayat Adepeju Olowookere 9 , Olawale Sunday Animasaun 10 , Charles Egede Ugwu 11 , Solomon Oloche Onoja 12 , Abdullahi Sani Gadama 13 , Musa Mohammed 14 , Isa Muhammad Daneji 13 , Dele Ohinoyi Amadu 15 , Peter Elisha Ghamba 16 , Nkechi Blessing Onukegbe 17 , Muhammad Sagir Shehu 18 , Chiladi Isomah 19 , Adamu Babayo 13 , Abdurrahman El-Fulaty Ahmad 1
Affiliations
- PMID: 32936732
- DOI: 10.1080/21645515.2020.1812313
Abstract
The incidence and case-fatality rates (CFRs) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, the etiological agent for Coronavirus Disease 2019 (COVID-19), have been rising unabated. Even though the entire world has been implementing infection prevention and control measures, the pandemic continues to spread. It has been widely accepted that preventive vaccination strategies are the public health measures for countering this pandemic. This study critically reviews the latest scientific advancement in genomics, replication pattern, pathogenesis, and immunopathology of SARS-CoV-2 infection and how these concepts could be used in the development of vaccines. We also offer a detailed discussion on the anticipated potency, efficacy, safety, and pharmaco-economic issues that are and will be associated with candidate COVID-19 vaccines.
Keywords: COVID-19; Host-virus interaction; SARS-CoV-2; Vaccine discovery.